https://m2.mtmt.hu/ hun 2026-09-22 03:30 JournalArticle 35593109 VALIDATED true Funding Agency and Grant Number: Croatian Science Foundation; European Regional Development Fund [KK.01.1.1.02.0016, KK.01.1.1.02.0021]; [IP-2022-10-6033] Funding text: The research was funded by the Croatian Science Foundation (project IP-2022-10-6033) and supported by the European Regional Development Fund (infrastructural projects CIuK, KK.01.1.1.02.0016, and FarmInova, KK.01.1.1.02.0021). 0 false 2026-09-18T07:01:59.714+0000 2025-08-27T10:42:13.177+0000 2024-11-21T12:25:38.866+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-02-10T15:14:11.623+0000 2025-02-18T09:28:15.296+0000 true 10093409 Miskolczi Éva /api/admin/10093409 Admin Miskolczi Éva (SE_KK_Admin5_DME, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Klarić, David true true /api/journal/10022148 REVIEWED PHARMACEUTICS 1999-4923 true false 10022148 false 10022148 true 1999-4923 Journal FOREIGN 16 12 1493 1493 17 2024 Background: Nabumetone (NAB) is a poorly soluble nonsteroidal anti-inflammatory prodrug (BCS class II drug) whose solubility is significantly improved by complexation with cyclodextrins (CDs). Methods: The solid complexes, in a 1:1 molar ratio, were prepared by mechanochemical activation by grinding, using β-cyclodextrin (β-CD) and its derivatives, hydroxypropyl- and sulfobutylether-β-cyclodextrin (HP-β-CD and SBE-β-CD). The complexation was confirmed by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and attenuated total reflectance Fourier-transformed infrared spectroscopy (ATR–FTIR). Obtained products were further characterized regarding their solubility, in vitro dissolution, permeability and chemical stability. Results: Co-grinding with HP-β-CD and SBE-β-CD yielded products that showed in vitro dissolution profiles in hydrochloric acid medium (pH 1.2) that were substantially different from that of pure NAB, yielding dissolution efficiency enhancements of 34.86 ± 1.64 and 58.30 ± 0.28 times, respectively, for the optimized products. Their in vitro dissolution and gastrointestinal permeability were also studied in a low-volume environment at pH 6.8, corresponding to the intestinal environment. Both β-CD derivatives increased NAB dissolution rate and NAB mass transport across the biomimetic membrane. The effect of β-CD derivatives on NAB chemical stability was studied under the stress conditions by the developed and validated UHPLC–DAD–HRMS method. In acidic conditions, pure and complexed NAB was prone to hydrolytic degradation, yielding one degradation product—pharmacologically inactive NAB metabolite. However, under the oxidative conditions at elevated temperatures, 10 NAB degradation products were identified from co-ground samples. All systems were stable during photo- and long-term stability studies. Conclusions: NAB complexes with HP-β-CD and SBE-β-CD are promising candidates for pharmaceutical product development. Funding 2049862 /api/funding/2049862 (IP-2022-10-6033) false true true true 2024 true true true false true false GOLD 2026-09-18 false http://www.mdpi.com/journal/pharmaceutics/ 5 0 5 2 0 5 5 5 5 5 5 2 2 2 3 0 5 2 5 2 0 3 3 Folyóiratcikk Journal Article 24 5 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 3 0 3 0 2026 0 2 2 2 2 D1 false false false false 2025-01-06T10:26:09.275+0000 Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); Gyógyszerészi Kémiai Intézet (SE / GYTK) 3 18 2 7 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 121766531 /api/authorship/121766531 Klarić, David 1 0.14285715 true false false Klarić David true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766532 /api/authorship/121766532 Soldin, Željka 2 0.14285715 false false false Soldin Željka true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766533 /api/authorship/121766533 Vincze, Anna [Vincze, Anna (Gyógyszerkémia), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 3 0.143 false false false Author 10071360 /api/author/10071360 Vincze Anna (Gyógyszerkémia) Vincze Anna true true Vincze Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766534 /api/authorship/121766534 Szolláth, Rita [Szolláth, Rita Mariann (Szolláth Rita), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 4 0.143 false false false Author 10080504 /api/author/10080504 Szolláth Rita Mariann (Szolláth Rita) Szolláth Rita Mariann true true Szolláth Rita true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766535 /api/authorship/121766535 Balogh, György Tibor [Balogh, György Tibor (Gyógyszerkémia), szerző] Gyógyszerészi Kémiai Intézet (SE / GYTK); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 5 0.143 false false false Author 10011949 /api/author/10011949 Balogh György Tibor (Gyógyszerkémia) Balogh György Tibor true 10011949 true Balogh György Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766536 /api/authorship/121766536 Jug, Mario ✉ 6 0.143 false false true Jug Mario true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 121766537 /api/authorship/121766537 Galić, Nives ✉ 7 0.143 false true true Galić Nives true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 27989962 /api/publicationidentifier/27989962 DOI: 10.3390/pharmaceutics16121493 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/pharmaceutics16121493 https://doi.org/10.3390/pharmaceutics16121493 false true PublicationIdentifier 28163329 /api/publicationidentifier/28163329 WoS: 001384004600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001384004600001 https://www.webofscience.com/wos/woscc/full-record/001384004600001 true true PublicationIdentifier 28163330 /api/publicationidentifier/28163330 Scopus: 85213299617 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85213299617 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85213299617 true true PublicationIdentifier 28418472 /api/publicationidentifier/28418472 PubMed: 39771473 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39771473 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39771473&dopt=Abstract false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11491011 /api/sjrrating/11491011 sjr:D1 (2024) Scopus - Pharmaceutical Science PHARMACEUTICS 1999-4923 18 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3003 /api/classificationexternal/3003 Scopus - Pharmaceutical Science true 3003 true D1 DIRECT true true Reference 60082924 /api/reference/60082924 1. Jansook 2018: Cyclodextrins: Structure, Physicochemical Properties and Pharmaceutical Applications., Int. J. Pharm., 535, p. 272, DOI: 10.1016/j.ijpharm.2017.11.018 1 10.1016/j.ijpharm.2017.11.018 false true Reference 60082925 /api/reference/60082925 2. Kali 2024: Cyclodextrins and Derivatives in Drug Delivery: New Developments, Relevant Clinical Trials, and Advanced Products., Carbohydr. Polym., 324, p. 121500, DOI: 10.1016/j.carbpol.2023.121500 2 10.1016/j.carbpol.2023.121500 false true Reference 60082926 /api/reference/60082926 3. Riccio 2023: Biopharmaceutical and Nanotoxicological Aspects of Cyclodextrins for Non-Invasive Topical Treatments: A Critical Review., J. Appl. Toxicol., 43, p. 1410, DOI: 10.1002/jat.4429 3 10.1002/jat.4429 false true Reference 60082927 /api/reference/60082927 4. Aiassa, V., Garnero, C., Zoppi, A., and Longhi, M.R. (2023). Cyclodextrins and Their Derivatives as Drug Stability Modifiers. Pharmaceuticals, 16., DOI: 10.3390/ph16081074 4 10.3390/ph16081074 false true Reference 60082928 /api/reference/60082928 5. Kovacs, T., Nagy, P., Panyi, G., Szente, L., Varga, Z., and Zakany, F. (2022). Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?. Pharmaceutics, 14., DOI: 10.3390/pharmaceutics14122559 5 10.3390/pharmaceutics14122559 false true Reference 60082929 /api/reference/60082929 6. Ferreira 2022: Cyclodextrin-Based Delivery Systems in Parenteral Formulations: A Critical Update Review., Eur. J. Pharm. Biopharm., 178, p. 35, DOI: 10.1016/j.ejpb.2022.07.007 6 10.1016/j.ejpb.2022.07.007 false true Reference 60082930 /api/reference/60082930 7. Jacob 2018: Cyclodextrin Complexes: Perspective from Drug Delivery and Formulation., Drug Dev. Res., 79, p. 201, DOI: 10.1002/ddr.21452 7 10.1002/ddr.21452 false true Reference 60082931 /api/reference/60082931 8. Kelrajter 2024: Inclusion Complexes of Nabumetone with β-Cyclodextrins: Spectroscopic, Spectrometric and Calorimetric Studies in Solution., J. Mol. Liq., 397, p. 124152, DOI: 10.1016/j.molliq.2024.124152 8 10.1016/j.molliq.2024.124152 false true Reference 60082932 /api/reference/60082932 9. Jug 2021: Investigation of Praziquantel/Cyclodextrin Inclusion Complexation by NMR and LC-HRMS/MS: Mechanism, Solubility, Chemical Stability, and Degradation Products., Mol. Pharm., 18, p. 4210, DOI: 10.1021/acs.molpharmaceut.1c00716 9 10.1021/acs.molpharmaceut.1c00716 false true Reference 60082933 /api/reference/60082933 10. Hoelm 2024: Inclusion Complexes of Loratadine with β-Cyclodextrin and Its Derivatives in Solution. Integrated Spectroscopic, Thermodynamic and Computational Studies., J. Mol. Liq., 410, p. 125515, DOI: 10.1016/j.molliq.2024.125515 10 10.1016/j.molliq.2024.125515 false true Reference 60082934 /api/reference/60082934 11. Mura 2015: Analytical Techniques for Characterization of Cyclodextrin Complexes in the Solid State: A Review., J. Pharm. Biomed. Anal., 113, p. 226, DOI: 10.1016/j.jpba.2015.01.058 11 10.1016/j.jpba.2015.01.058 false true Reference 60082935 /api/reference/60082935 12. Jug, M., and Mura, P.A. (2018). Grinding as Solvent-Free Green Chemistry Approach for Cyclodextrin Inclusion Complex Preparation in the Solid State. Pharmaceutics, 10., DOI: 10.3390/pharmaceutics10040189 12 10.3390/pharmaceutics10040189 false true Reference 60082936 /api/reference/60082936 13. Nicoletti 2020: An Improved Method for the Preparation of β-Lapachone:2-Hydroxypropyl-β-Cyclodextrin Inclusion Complexes., J. Drug Deliv. Sci. Technol., 58, p. 101777, DOI: 10.1016/j.jddst.2020.101777 13 10.1016/j.jddst.2020.101777 false true Reference 60082937 /api/reference/60082937 14. Guadarrama 2023: Inclusion and Non-Inclusion Complexes between Curcumin and β-Cyclodextrin with High-Curcumin Loading and Enhanced Aqueous Solubility Obtained by Mechanochemistry., ChemistrySelect, 8, p. e202303254, DOI: 10.1002/slct.202303254 14 10.1002/slct.202303254 false true Reference 60082938 /api/reference/60082938 15. Bannwarth 2008: Safety of the Nonselective NSAID Nabumetone: Focus on Gastrointestinal Tolerability., Drug Saf., 31, p. 485, DOI: 10.2165/00002018-200831060-00004 15 10.2165/00002018-200831060-00004 false true Reference 60082939 /api/reference/60082939 16. Hedner 2004: Nabumetone: Therapeutic Use and Safety Profile in the Management of Osteoarthritis and Rheumatoid Arthritis., Drugs, 64, p. 2315, DOI: 10.2165/00003495-200464200-00004 16 10.2165/00003495-200464200-00004 false true Reference 60082940 /api/reference/60082940 17. Bensouilah 2017: Host-Guest Complex of Nabumetone: β-Cyclodextrin: Quantum Chemical Study and QTAIM Analysis., J. Incl. Phenom. Macrocycl. Chem., 87, p. 191, DOI: 10.1007/s10847-016-0690-4 17 10.1007/s10847-016-0690-4 false true Reference 60082941 /api/reference/60082941 18. 2005: Interactions of Nabumetone with γ-Cyclodextrin Studied by Fluorescence Measurements., J. Incl. Phenom. Macrocycl. Chem., 51, p. 27, DOI: 10.1007/s10847-004-1502-9 18 10.1007/s10847-004-1502-9 false true Reference 60082942 /api/reference/60082942 19. Valero 2007: Encapsulation of Nabumetone by Means of Drug: (β-Cyclodextrin)2:Polyvinylpyrrolidone Ternary Complex Formation., J. Lumin., 126, p. 297, DOI: 10.1016/j.jlumin.2006.07.028 19 10.1016/j.jlumin.2006.07.028 false true Reference 60082943 /api/reference/60082943 20. Goyenechea 2002: Interactions of Nabumetone with Cyclodextrins in Solution and in the Solid State., J. Incl. Phenom. Macrocycl. Chem., 44, p. 283, DOI: 10.1023/A:1023016114329 20 10.1023/A:1023016114329 false true Reference 60082944 /api/reference/60082944 21. (2024). 5.17.1. Recommendations on Dissolution Testing. European Pharmacopeia, EDQM Council of Europe. 21 false true Reference 60082945 /api/reference/60082945 22. Su 2009: Micronization of Nabumetone Using the Rapid Expansion of Supercritical Solution (RESS) Process., J. Supercrit. Fluids, 50, p. 69, DOI: 10.1016/j.supflu.2009.04.013 22 10.1016/j.supflu.2009.04.013 false true Reference 60082946 /api/reference/60082946 23. Anderson 1998: An Evaluation of Fit Factors and Dissolution Efficiency for the Comparison of in Vitro Dissolution Profiles., J. Pharm. Biomed. Anal., 17, p. 811, DOI: 10.1016/S0731-7085(98)00011-9 23 10.1016/S0731-7085(98)00011-9 false true Reference 60082947 /api/reference/60082947 24. Xie 2015: In Vitro Dissolution Similarity Factor (F2) and in Vivo Bioequivalence Criteria, How and When Do They Match? Using a BCS Class II Drug as a Simulation Example., Eur. J. Pharm. Sci., 66, p. 163, DOI: 10.1016/j.ejps.2014.10.002 24 10.1016/j.ejps.2014.10.002 false true Reference 60082948 /api/reference/60082948 25. (2024, October 07). ICH Q1B, Stability Testing: Photostability Testing of New Drug Substances and Products. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-b-photostability-testing-new-active-substances-and-medicinal-products-step-5_en.pdf. 25 false true Reference 60082949 /api/reference/60082949 26. Price 2002: Polymorphism of Nabumetone., Cryst. Growth Des., 2, p. 501, DOI: 10.1021/cg0255568 26 10.1021/cg0255568 false true Reference 60082950 /api/reference/60082950 27. Bolten 2016: Polymorphic Properties of Micronized Mefenamic Acid, Nabumetone, Paracetamol and Tolbutamide Produced by Rapid Expansion of Supercritical Solutions (RESS)., J. Supercrit. Fluids, 116, p. 239, DOI: 10.1016/j.supflu.2016.06.001 27 10.1016/j.supflu.2016.06.001 false true Reference 60082951 /api/reference/60082951 28. Chyall 2002: Polymorph Generation in Capillary Spaces: The Preparation and Structural Analysis of a Metastable Polymorph of Nabumetone., Cryst. Growth Des., 2, p. 505, DOI: 10.1021/cg0200311 28 10.1021/cg0200311 false true Reference 60082952 /api/reference/60082952 29. Suresh 2019: Far-Infrared Spectroscopy as a Probe for Polymorph Discrimination., J. Pharm. Sci., 108, p. 1915, DOI: 10.1016/j.xphs.2018.12.020 29 10.1016/j.xphs.2018.12.020 false true Reference 60082953 /api/reference/60082953 30. Tan 2016: Towards Medicinal Mechanochemistry: Evolution of Milling from Pharmaceutical Solid Form Screening to the Synthesis of Active Pharmaceutical Ingredients (APIs)., Chem. Commun., 52, p. 7760, DOI: 10.1039/C6CC02015A 30 10.1039/C6CC02015A false true Reference 60082954 /api/reference/60082954 31. Julien 2022: Methods for Monitoring Milling Reactions and Mechanistic Studies of Mechanochemistry: A Primer., Cryst. Growth Des., 22, p. 5726, DOI: 10.1021/acs.cgd.2c00587 31 10.1021/acs.cgd.2c00587 false true Reference 60082955 /api/reference/60082955 32. Govindasamy 2015: Experimental and Theoretical Studies of (FT-IR, FT-Raman, UV–Visible and DFT) 4-(6-Methoxynaphthalen-2-Yl) Butan-2-One., Spectrochim. Acta A Mol. Biomol. Spectrosc., 149, p. 800, DOI: 10.1016/j.saa.2015.04.043 32 10.1016/j.saa.2015.04.043 false true Reference 60082956 /api/reference/60082956 33. Crupi 2008: Physicochemical Characterization of Coumestrol/β-Cyclodextrins Inclusion Complexes by UV–Vis and FTIR-ATR Spectroscopies., Vib. Spectrosc., 48, p. 172, DOI: 10.1016/j.vibspec.2007.12.013 33 10.1016/j.vibspec.2007.12.013 false true Reference 60082957 /api/reference/60082957 34. Mennini 2014: Physico-Chemical Characterization in Solution and in the Solid State of Clonazepam Complexes with Native and Chemically-Modified Cyclodextrins., J. Pharm. Biomed. Anal., 89, p. 142, DOI: 10.1016/j.jpba.2013.11.009 34 10.1016/j.jpba.2013.11.009 false true Reference 60082958 /api/reference/60082958 35. Jablan 2013: Zaleplon Co-Ground Complexes with Natural and Polymeric β-Cyclodextrin., J. Incl. Phenom. Macrocycl. Chem., 76, p. 353, DOI: 10.1007/s10847-012-0206-9 35 10.1007/s10847-012-0206-9 false true Reference 60082959 /api/reference/60082959 36. Jablan 2017: Biopharmaceutical Characterization of Praziquantel Cocrystals and Cyclodextrin Complexes Prepared by Grinding., J. Pharm. Biomed. Anal., 137, p. 42, DOI: 10.1016/j.jpba.2017.01.025 36 10.1016/j.jpba.2017.01.025 false true Reference 60082960 /api/reference/60082960 37. Jug 2018: An Overview of in Vitro Dissolution/Release Methods for Novel Mucosal Drug Delivery Systems., J. Pharm. Biomed. Anal., 147, p. 350, DOI: 10.1016/j.jpba.2017.06.072 37 10.1016/j.jpba.2017.06.072 false true Reference 60082961 /api/reference/60082961 38. Lex 2022: Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms., AAPS J., 24, p. 40, DOI: 10.1208/s12248-022-00690-5 38 10.1208/s12248-022-00690-5 false true Reference 60082962 /api/reference/60082962 39. Grignard 2017: Considerations for the Development of in Vitro Dissolution Tests to Reduce or Replace Preclinical Oral Absorption Studies., Eur. J. Pharm. Sci., 99, p. 193, DOI: 10.1016/j.ejps.2016.12.004 39 10.1016/j.ejps.2016.12.004 false true Reference 60082963 /api/reference/60082963 40. USP (2024). Monographs, Nabumetone Tablets. United States Pharmacopeia, The United State Pharmacopoeial Convention. 40 false true Reference 60082964 /api/reference/60082964 41. Hao 2023: Inclusion Complexation of Surfactant with β-Cyclodextrin and Its Effect on the Mixed Micellization of Cationic/Anionic Surfactants., Colloids. Surf. A Physicochem. Eng. Asp., 668, p. 131437, DOI: 10.1016/j.colsurfa.2023.131437 41 10.1016/j.colsurfa.2023.131437 false true Reference 60082965 /api/reference/60082965 42. Kennedy 2024: Bioequivalence Prediction with Small-Scale Biphasic Dissolution and Simultaneous Dissolution-Permeation Apparatus—An Aripiprazole Case Study., Eur. J. Pharm. Sci., 198, p. 106782, DOI: 10.1016/j.ejps.2024.106782 42 10.1016/j.ejps.2024.106782 false true Reference 60082966 /api/reference/60082966 43. Karkossa 2017: Assessing the Influence of Media Composition and Ionic Strength on Drug Release from Commercial Immediate-Release and Enteric-Coated Aspirin Tablets., J. Pharm. Pharmacol., 69, p. 1327, DOI: 10.1111/jphp.12777 43 10.1111/jphp.12777 false true Reference 60082967 /api/reference/60082967 44. Sripetch 2022: Cyclodextrins and Drug Membrane Permeation: Thermodynamic Considerations., J. Pharm. Sci., 111, p. 2571, DOI: 10.1016/j.xphs.2022.04.015 44 10.1016/j.xphs.2022.04.015 false true Reference 60082968 /api/reference/60082968 45. Scarpignato 2013: Piroxicam-ß-Cyclodextrin: A GI Safer Piroxicam., Curr. Med. Chem., 20, p. 2415, DOI: 10.2174/09298673113209990115 45 10.2174/09298673113209990115 false true Reference 60082969 /api/reference/60082969 46. Popielec 2017: Effects of Cyclodextrins on the Chemical Stability of Drugs., Int. J. Pharm., 531, p. 532, DOI: 10.1016/j.ijpharm.2017.06.009 46 10.1016/j.ijpharm.2017.06.009 false true Reference 60082970 /api/reference/60082970 47. Narayanam 2014: Critical Practical Aspects in the Application of Liquid Chromatography–Mass Spectrometric Studies for the Characterization of Impurities and Degradation Products., J. Pharm. Biomed. Anal., 87, p. 191, DOI: 10.1016/j.jpba.2013.04.027 47 10.1016/j.jpba.2013.04.027 false true Reference 60082971 /api/reference/60082971 48. Valero 2003: Photodegradation of Nabumetone in Aqueous Solutions., J. Photochem. Photobiol. A. Chem., 157, p. 93, DOI: 10.1016/S1010-6030(03)00013-3 48 10.1016/S1010-6030(03)00013-3 false true Reference 60082972 /api/reference/60082972 49. Wolff 2001: The Use of Particle Beam Mass Spectrometry for the Measurement of Impurities in a Nabumetone Drug Substance, Not Easily Amenable to Atmospheric Pressure Ionisation Techniques., Rapid. Commun. Mass. Spectrom., 15, p. 265, DOI: 10.1002/rcm.214 49 10.1002/rcm.214 false true Reference 60082973 /api/reference/60082973 50. Nobilis 2013: Analytical Power of LLE–HPLC–PDA–MS/MS in Drug Metabolism Studies: Identification of New Nabumetone Metabolites., J. Pharm. Biomed. Anal., 80, p. 164, DOI: 10.1016/j.jpba.2013.03.006 50 10.1016/j.jpba.2013.03.006 false true Reference 60082974 /api/reference/60082974 51. Nobilis 2003: Comparative Biotransformation and Disposition Studies of Nabumetone in Humans and Minipigs Using High-Performance Liquid Chromatography with Ultraviolet, Fluorescence and Mass Spectrometric Detection., J. Pharm. Biomed. Anal., 32, p. 641, DOI: 10.1016/S0731-7085(03)00171-7 51 10.1016/S0731-7085(03)00171-7 false true Reference 60082975 /api/reference/60082975 52. Szente 2016: Analytical Characterization of Cyclodextrins: History, Official Methods and Recommended New Techniques., J. Pharm. Biomed. Anal., 130, p. 347, DOI: 10.1016/j.jpba.2016.05.009 52 10.1016/j.jpba.2016.05.009 false true Reference 60082976 /api/reference/60082976 53. Saokham, P., Muankaew, C., Jansook, P., and Loftsson, T. (2018). Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. Molecules, 23., DOI: 10.3390/molecules23051161 53 10.3390/molecules23051161 false true Reference 60082977 /api/reference/60082977 54. Gabrić, A., Hodnik, Ž., and Pajk, S. (2022). Oxidation of Drugs during Drug Product Development: Problems and Solutions. Pharmaceutics, 14., DOI: 10.3390/pharmaceutics14020325 54 10.3390/pharmaceutics14020325 false true /api/publication/35593109 Klarić David et al. Biopharmaceutical Characterization and Stability of Nabumetone–Cyclodextrins Complexes Prepared by Grinding. (2024) PHARMACEUTICS 1999-4923 16 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Klarić David </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Soldin Željka </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10071360"><a href="/gui2/?type=authors&mode=browse&sel=10071360" target="_blank">Vincze Anna (<span class="authorship-author-name">Vincze Anna</span> <span class="authorAux-mtmt"> Gyógyszerkémia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10080504"><a href="/gui2/?type=authors&mode=browse&sel=10080504" target="_blank">Szolláth Rita (<span class="authorship-author-name">Szolláth Rita Mariann</span> <span class="authorAux-mtmt"> Szolláth Rita</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10011949"><a href="/gui2/?type=authors&mode=browse&sel=10011949" target="_blank">Balogh György Tibor (<span class="authorship-author-name">Balogh György Tibor</span> <span class="authorAux-mtmt"> Gyógyszerkémia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerészi Kémiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Jug Mario ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Galić Nives ✉ </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35593109" target="_blank">Biopharmaceutical Characterization and Stability of Nabumetone–Cyclodextrins Complexes Prepared by Grinding</a></div> <div> <span class="journal-title">PHARMACEUTICS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/1999-4923">1999-4923</a>)</span>: <span class="journal-volume">16</span> <span class="journal-issue">12</span> <span class="page"> Paper 1493. 17 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/pharmaceutics16121493" target="_blank" href="https://doi.org/10.3390/pharmaceutics16121493"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001384004600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001384004600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85213299617" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85213299617"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39771473" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39771473&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmaceutical Science&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 5</span> | Független: 2 | Függő: 3 | Nem jelölt: 0 | WoS jelölt: 5 | Scopus jelölt:&nbsp;5 | WoS/Scopus jelölt:&nbsp;5 | DOI jelölt:&nbsp;5 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35593109&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 3 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35593109</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (IP-2022-10-6033) </div> <div class="lastModified">Utolsó módosítás: 2025.08.27. 12:42 Andódy Katalin (BME admin4) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Funding Agency and Grant Number: Croatian Science Foundation; European Regional Development Fund [KK.01.1.1.02.0016, KK.01.1.1.02.0021]; [IP-2022-10-6033] Funding text: The research was funded by the Croatian Science Foundation (project IP-2022-10-6033) and supported by the European Regional Development Fund (infrastructural projects CIuK, KK.01.1.1.02.0016, and FarmInova, KK.01.1....</pre> </div></div>